XML 32 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation
3 Months Ended
Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-based Compensation

10.

Stock-based Compensation

 

On February 6, 2020, the Company amended the Company’s 2015 New Employee Incentive Plan (the “2015 Plan”) to increase the total number of shares of common stock reserved for issuance under the plan by 250,000 shares. Awards may only be granted under the 2015 Plan to employees who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as a material inducement to entering into employment with the Company. As of March 31, 2022, there were 90,389 shares of common stock remaining and available for future issuances under the 2015 Plan.

 

On June 16, 2020, the stockholders of the Company approved the Company’s 2020 Stock Incentive Plan (the “2020 Plan”), which replaced the Company’s 2014 Equity Incentive Plan. The 2020 Plan provides for the award or sale of shares of common stock (including restricted stock), the award of stock units and stock appreciation rights, and the grant of both incentive stock options to purchase common stock. The 2020 Plan provides for the issuance of up to 550,000 shares of common stock, and the number of shares available for issuance will be increased to the extent that awards granted under the 2020 Plan and the Company’s 2014 Equity Incentive Plan are forfeited or expire (except as otherwise provided in the 2020 Plan). On May 17, 2021, the stockholders of the Company approved an amendment and restatement to the 2020 Plan to increase the total number of shares of common stock reserved for issuance under the 2020 Plan by 1,000,000 shares. As of March 31, 2022, there were 640,212 shares remaining and available for future issuances under the 2020 Plan.

 

Generally, options issued under the 2020 Plan are subject to a two-year or four-year vesting schedule with 25% of the options vesting one year anniversary of the grant date followed by equal monthly installment vesting, and have a contractual term of 10 years.

 

A summary of activity for the three months ended March 31, 2022 is as follows:

 

 

 

Options

 

 

Weighted

Average

Exercise Price

 

 

Weighted

Average

Remaining

Contractual

Term (years)

 

 

Aggregate

Intrinsic Value

 

Balance as of December 31, 2021

 

 

1,170,890

 

 

$

5.01

 

 

 

9.00

 

 

 

 

 

Granted

 

 

 

 

$

 

 

 

 

 

 

 

 

 

Cancelled/forfeited

 

 

(17

)

 

$

24,706.00

 

 

 

 

 

 

 

 

 

Balance as of March 31, 2022

 

 

1,170,873

 

 

$

4.65

 

 

 

8.75

 

 

$

-

 

Vested and expected to vest at March 31, 2022

 

 

460,217

 

 

$

8.04

 

 

 

8.47

 

 

$

-

 

Exercisable at March 31, 2022

 

 

1,102,117

 

 

$

4.74

 

 

 

8.73

 

 

$

-

 

 

As of March 31, 2022, the total compensation cost related to non-vested stock options not yet recognized for all the Company’s plans is approximately $1.3 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 2.79 years.